Oklo (OKLO) said Wednesday it has closed its $25 million all-stock acquisition of Atomic Alchemy.
The company said the acquisition is expected to have "minimal immediate impact" on its operating costs and 2025 outlook.
Oklo said the acquisition also enhances its ability to provide a domestic supply chain of radioisotopes for healthcare, research, and defense.
Atomic Alchemy will operate as a subsidiary under its own brand, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.